Management of prostate cancer

Area of Science:

• Urology
• Oncology
• Diagnostic Medicine

Background:

• Prostate cancer is a significant cause of mortality in the UK, with increasing diagnoses via prostate-specific antigen (PSA) screening.
• Autopsy studies reveal a high prevalence of latent prostate cancer, with many cases showing local invasion.
• Distinguishing between indolent and lethal prostate cancers is a major challenge in urology.

Purpose of the Study:

• To highlight the challenges in prostate cancer diagnosis and management.
• To discuss the limitations of PSA screening in identifying clinically significant disease.
• To emphasize the importance of pre-test counselling for PSA testing.

Main Methods:

• Review of existing literature on prostate cancer prevalence, natural history, and PSA screening.
• Analysis of diagnostic challenges in differentiating indolent from aggressive forms of prostate cancer.
• Discussion of current guidelines and recommendations for PSA testing.

Main Results:

• PSA screening has low specificity for clinically significant prostate cancer, and population-wide screening is not recommended.
• A significant proportion of prostate cancers identified through screening may be indolent and not require immediate intervention.
• The natural history of early prostate cancer remains unclear, complicating treatment decisions.

Conclusions:

• PSA testing requires careful consideration and pre-test counselling due to its limitations.
• The decision to undertake PSA testing should involve a healthcare professional, such as a General Practitioner (GP) or urologist.
• Further research is needed to improve the accuracy of prostate cancer detection and risk stratification.